Lennar vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Second-largest US homebuilder; 80,000 homes FY2024; $35.4B revenue; Millrose Properties land REIT spin-off announced 2024 to create capital-light homebuilder model; "Everything's Included" strategy.
About
Lennar Corporation is the second-largest homebuilder in the United States by revenue, founded in 1954 by Leonard Miller and Arnold Rosen in Miami, Florida, where it remains headquartered, trading on NYSE (LEN). The company delivered approximately 80,000 homes in fiscal year 2024 (ending November 30) and generated approximately $35.4 billion in revenues under Executive Chairman Stuart Miller, with Jon Jaffe and Diane Bessette serving as co-CEOs. Lennar builds homes across entry-level, move-up, and active adult buyer segments in 26 states and over 100 metropolitan markets, with significant concentration in Florida, Texas, California, Georgia, and North Carolina—America's fastest-growing metropolitan areas where household formation and domestic migration trends support sustained demand. Lennar's "Everything's Included" merchandising strategy bundles premium features into base home prices, simplifying the purchase experience and improving per-home revenue per square foot versus competitors offering extensive à la carte options.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.